Shin‐ichi Harashima

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial

Christopher Sorli, Shin‐ichi Harashima, George Tsoukas et al. · The Lancet Diabetes & Endocrinology · 2017 · 648 citations · Full text

Diabetes Management, Sustain 1, Diabetes +7

Mechanisms for cytotoxic effects of anti–tumor necrosis factor agents on transmembrane tumor necrosis factor α–expressing cells: Comparison among infliximab, etanercept, and adalimumab

Hiroki Mitoma, Takahiko Horiuchi, Hiroshi Tsukamoto et al. · Arthritis & Rheumatism · 2008 · 343 citations

Apoptosis, Immunology, Immune Regulation +26

Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-α

Hiroki Mitoma, Takahiko Horiuchi, Nobuaki Hatta et al. · Gastroenterology · 2005 · 265 citations

Inflammation, Cytokine, Anti-inflammatory +14

Outside-to-Inside Signal Through the Membrane TNF-α Induces E-Selectin (CD62E) Expression on Activated Human CD4+ T Cells

Shin‐ichi Harashima, Takahiko Horiuchi, Nobuaki Hatta et al. · The Journal of Immunology · 2001 · 130 citations · Full text

Association of tumor necrosis factor receptor type II polymorphism 196R with systemic lupus erythematosus in the Japanese: Molecular and functional analysis

Chika Morita, Takahiko Horiuchi, Hiroshi Tsukamoto et al. · Arthritis & Rheumatism · 2001 · 128 citations